Treatment of Advanced or Metastatic Typical Lung Carcinoid and Slowly Progressing SRI-Positive Lung Carcinoid
Clinical Scenario
This first-line protocol addresses patients with advanced or metastatic typical lung carcinoid, and those with slowly progressing somatostatin receptor imaging (SRI)-positive lung carcinoid. Watchful follow-up may be appropriate for asymptomatic patients with slowly radiologically progressing disease.
First-Line Treatment Approach
Management in this setting is guided by a dacarbazine/temozolomide-based chemotherapy strategy. The full regimen — including specific agent selection, combinations, and sequencing — is detailed in the structured protocol.
Complete regimen details, including all treatment options and clinical guidance, are available behind the link below.
References
DOI: 10.1016/j.annonc.2021.01.003
- SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]
- Watchful follow-up may be considered in asymptomatic patients with slowly radiologically progressing LCs [V, C]
- Dacarbazine/temozolomide-based ChT as first line, and platinum-based ChT as second line, are recommended in advanced LC patients refractory or intolerant to everolimus therapy [IV, C]
- Due to better tolerance and convenience, we recommend temozolomide (± capecitabine) as first-line and platinum-based ChT as second-line options in patients with progressive advanced LC [IV, C]
View source ↗